These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21558077)

  • 1. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
    Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
    Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
    Chamberlain MC; Glantz MJ; Fadul CE
    Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
    Rammo R; Rock A; Transou A; Raghunathan A; Rock J
    J Neurosurg; 2016 Feb; 124(2):496-500. PubMed ID: 26274993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
    Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
    J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of recurrent meningeal hemangiopericytoma.
    Galanis E; Buckner JC; Scheithauer BW; Kimmel DW; Schomberg PJ; Piepgras DG
    Cancer; 1998 May; 82(10):1915-20. PubMed ID: 9587125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Chamberlain MC
    Neurology; 2015 Sep; 85(12):1090. PubMed ID: 26391415
    [No Abstract]   [Full Text] [Related]  

  • 11. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.
    Alexandru D; Glantz MJ; Kim L; Chamberlain MC; Bota DA
    Cancer; 2011 Oct; 117(19):4506-11. PubMed ID: 21446045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual improvement during octreotide therapy in a case of episellar meningioma.
    Jaffrain-Rea ML; Minniti G; Santoro A; Bastianello S; Tamburrano G; Gulino A; Cantore G
    Clin Neurol Neurosurg; 1998 Mar; 100(1):40-3. PubMed ID: 9637203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment: Medical therapy for recurrent or progressive meningiomas remains elusive.
    Iwamoto FM
    Neurology; 2015 Jan; 84(3):285. PubMed ID: 25527267
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical and anaplastic meningiomas treated with bevacizumab.
    Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
    J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [X-ray computed tomographic aspects of malignant meningioma and meningeal hemangiopericytoma].
    Dufresne MC; Bédard F
    Can Assoc Radiol J; 1996 Aug; 47(4):279-87. PubMed ID: 8696997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy.
    Nicosia L; Bucpapaj R; Barresi V; Damante R; Napoli G; Ghimenton C; Giaj-Levra N; Cancedda M; Flaminio S; Figlia V; Alongi F
    Neurochirurgie; 2021 Apr; 67(2):193-197. PubMed ID: 33190809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.